Swedish-biotech Affibody AB and Italy-based Chiesi Group announced this week that the two have signed a collaboration and licensing agreement to develop and commercialize treatments for respiratory illnesses.
According to the agreement, the partners will leverage Affibody's proprietary technology and will work closely to progress up to three programs based on the molecules targeted. Chiesi will take over the funding for the discovery, development and commercialization costs, while Affibody has trained the option to promote in the Nordic Region.
Affibody first came into the scene in 2016, developing next generation protein drugs focused on indications and target proteins identified with its platforms, Affibody molecules and Albumod. Chiesi Group has over 85 years of experience as a research-focused biopharmaceuticals group that works on the development of drugs in respiratory health, rare diseases and specialty care.
Affibody is eligible to receive upfront, development, regulatory, and commercial milestone payments up to $637 million.
